• Daniel Herranz Benito
  • Daniel Herranz Benito
  • Assistant Professor
  • Department: Department of Pharmacology
  • Program(s): Cellular and Molecular Pharmacology Graduate Program, Microbiology and Molecular Genetics Graduate Program
  • Phone: 1.7322354064
  • Rutgers Robert Wood Johnson Medical School
  • Cancer Institute of NJ, Room 3026
  • 195 Little Albany Street
  • New Brunswick, NJ 08901
  • Key Words: Epigenetics, Leukemia, T-ALL, Chromosome conformation, Enhancers, Non-coding regions, Genetically Engineered Mouse Models (GEMM)
  • Lab Site URL

The Herranz lab is a new laboratory (starting July 2017) at the Cancer Institute of New Jersey and our long-term research goals are: (i) to discover and define how oncogenic and tumor suppressor enhancers impact tumorigenesis in hematological and solid tumors; (ii) to dissect the interplay between cancer cell-specific metabolic rewiring and epigenetics in T-cell Acute Lymphoblastic Leukemia (T-ALL). 

The first area of interest in the lab stems from our initial discovery of a Notch1-bound Myc enhancer (N-Me), as the long-sought missing link in the regulation of MYC by NOTCH1 in T-cells. Using an integrated analysis of human and mouse NOTCH1 ChIP-seq data, chromosome conformation capture analyses, reporter assays and novel mouse models, we demonstrated that N-Me loops with the MYC promoter in T-cells, inducing Myc expression in an orientation-independent but NOTCH1-dependent-manner. Moreover, experiments using N-Me knockout and conditional knockout mouse models showed that N-Me is critically required for the normal development of T-cells, as well as for the generation and maintenance of NOTCH1-induced T-ALL (Herranz et al, Nature Medicine 2014).  Our central hypothesis is that enhancer malfunction is a recurrent and significant hallmark of cancer in different tumor types. Moreover, we hypothesize that in addition to duplications of oncogenic enhancers, there will also occur deletions of tumor suppressor enhancers that control the expression of haploinsufficient tumor suppressor genes. Thus, our main goal is to discover and dissect novel oncogenic and tumor suppressor enhancers.

The second area of interest in the lab sprouts from our long-standing interest in the interplay between metabolism and epigenetics as a pathogenic mechanism of cancer. In particular, using a combination of gene expression profiling, metabolomic analyses, 13C isotope labeling experiments and state-of-the-art experimental therapeutics in vivo, we uncovered a critical role for the metabolic effects of NOTCH1 inhibition in the antileukemic activity of anti-NOTCH1 therapies. Specifically, these studies revealed that inhibition of NOTCH1 signaling elicits a global anabolic shutdown, forcing leukemic cells to use autophagy as a salvage pathway to support cell growth and demonstrated that these effects are rescued by isogenic loss of Pten. Moreover, these studies revealed a prominent role of glutaminolysis in feeding the tricaboxylic acid downstream of NOTCH1 in Pten-positive T-ALL. Consistent with these findings, autophagy inhibition or glutaminolysis inhibition, either by genetic or pharmacological means, show highly synergistic antileukemic effects with anti-NOTCH1 therapies in vivo (Herranz et al, Nature Medicine 2015).

Moving forward, we hypothesize that key regulators that affect both the epigenetic and metabolic status of cancer cells will act as master regulators of oncogenic transformation. As such, we will test the effects of different candidates on the metabolic and epigenetic landscape T-ALL in vivo. These experiments will open new therapeutic opportunities for the treatment of this disease.  Indeed, one of our most recent discoveries was the identification of the first in vivo inhibitor of Serine hydroximethyltransferase (SHMT), a critical enzyme in the folate pathway. In this study, we showed SHMT inhibition shows highly antileukemic effects in mouse primary leukemias and human T-ALL PDXs in vivo. Moreover, SHMT inhibition synergizes with methotrexate, and shows therapeutic activity even in cells resistant to methotrexate, thus uncovering a novel strategy to treat T-ALL patients (Garcia-Cañaveras*, Lancho* et al., Leukemia 2020)